医学
肝细胞癌
内科学
肿瘤科
免疫疗法
临床终点
总体生存率
临床试验
生存分析
治疗方式
荟萃分析
癌
梅德林
模式
完全响应
终点测定
治疗方式
肝细胞癌
存活率
外科
抗体疗法
随机对照试验
作者
Marta Fortuny,Antonio De Rosa,Ignacio Roca,Dan Ouchi,Elisaul Suárez,Andrea Cadiz,Mario Matute‐González,Andrew M. Moon,Jordi Rimola,Ferràn Torres,María Reig
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2025-12-15
卷期号:84 (5): 1371-1380
被引量:6
标识
DOI:10.1097/hep.0000000000001630
摘要
BACKGROUND AND AIMS: Macrovascular invasion (MaVI) defines advanced-stage hepatocellular carcinoma (HCC) and typically mandates systemic therapy, yet some guidelines advocate surgery or locoregional approaches. We conducted a systematic review and meta-analysis of overall survival (OS) in HCC with MaVI treated with approaches other than systemic therapy, enforcing stringent inclusion criteria to exclude studies lacking a minimal prognostic dataset and to improve cohort comparability. APPROACH AND RESULTS: PRISMA-guided methods were used (CRD420251051847). PubMed was searched (January 2008 to November 2024). Eligible studies reported OS for HCC with MaVI and provided baseline performance status and liver function; studies without adequate prognostic information were excluded. Data on OS at 1, 2, 3, and 5 years were extracted, and heterogeneity was assessed. Seventy-three studies met criteria (104 treatment arms; 10,329 patients). Despite a rigorous identification process, substantial heterogeneity persisted for most modalities ( I2 >80%), precluding robust pooling. Transarterial radioembolization (TARE) monotherapy was the only treatment with low heterogeneity ( I2 =0%) and showed a pooled 1-year OS of 34% (95% CI: 20%-48%). Apparent advantages of sequential strategies likely reflected confounding by indication and immortal-time bias, as only patients who lived long enough and were sufficiently fit proceeded through the full sequence. Data completeness declined beyond 12 months (missing OS: 0% at 1 y; 17.3% at 2 y; 32.7% at 3 y; 70.2% at 5 y). CONCLUSIONS: In HCC with MaVI, 1-year OS is the most comparable endpoint across modalities. This analysis identifies TARE as the only consistently reproducible option, showing a 1-year survival of 34%. In contrast, surgery and sequential therapies remain confounded by substantial heterogeneity. Accordingly, stratified head-to-head trials comparing alternative modalities against immunotherapy are warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI